Tjalf Ziemssen Selected Research

Prodrugs

11/2021

Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tjalf Ziemssen Research Topics

Disease

97	Multiple Sclerosis 11/2022 - 11/2002
41	Relapsing-Remitting Multiple Sclerosis 04/2022 - 09/2008
6	Progressive Multifocal Leukoencephalopathy 02/2022 - 04/2011
6	Disease Progression 01/2021 - 06/2016
6	Infections 01/2021 - 04/2011
5	Inflammation (Inflammations) 11/2021 - 12/2009
5	Fatigue 01/2017 - 09/2008
4	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 04/2011
4	Stroke (Strokes) 10/2021 - 02/2007
4	Chronic Progressive Multiple Sclerosis 10/2020 - 01/2017
3	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 12/2011
3	Optic Neuritis (Retrobulbar Neuritis) 12/2018 - 03/2017
3	Hypercholesterolemia 01/2013 - 12/2009
2	Hepatolenticular Degeneration (Wilson's Disease) 01/2022 - 01/2017
2	Neuroacanthocytosis 05/2021 - 01/2021
2	Nervous System Diseases (Neurological Disorders) 04/2021 - 05/2015
2	Seizures (Absence Seizure) 02/2021 - 07/2011
2	Weight Gain 01/2021 - 10/2018
2	Pain (Aches) 01/2021 - 12/2015
2	Bradycardia 01/2020 - 01/2017
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2020 - 01/2019
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2019 - 08/2007
2	Pulmonary Arterial Hypertension 07/2019 - 06/2014
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 09/2017
2	Obesity 01/2017 - 12/2009
2	Orthostatic Hypotension (Postural Hypotension) 01/2017 - 02/2010
2	Demyelinating Diseases (Demyelinating Disease) 01/2016 - 11/2005
2	Hyperlipidemias (Hyperlipidemia) 05/2015 - 05/2015
2	Coronary Artery Disease (Coronary Atherosclerosis) 05/2015 - 06/2014
2	Hyperhomocysteinemia 05/2015 - 05/2015
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2009 - 01/2004
1	COVID-19 11/2022
1	Hypoxia (Hypoxemia) 10/2022
1	Drug-Related Side Effects and Adverse Reactions 06/2022
1	Brain Injuries (Brain Injury) 01/2022
1	Nervous System Trauma 01/2022
1	Ulcerative Colitis 01/2022
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 10/2021
1	Sarcoma (Soft Tissue Sarcoma) 07/2021
1	Rare Diseases (Rare Disease) 05/2021
1	Injection Site Reaction 01/2021

Drug/Important Bio-Agent (IBA)

24	Fingolimod Hydrochloride (FTY720)FDA Link 06/2022 - 12/2013
18	Alemtuzumab (Campath)FDA Link 01/2022 - 01/2015
16	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 11/2002
15	Natalizumab (Tysabri)FDA Link 02/2022 - 09/2010
12	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
8	Retinaldehyde (Retinal)IBA 01/2021 - 08/2009
7	Pharmaceutical PreparationsIBA 01/2022 - 02/2010
6	Monoclonal AntibodiesIBA 11/2021 - 04/2011
4	Interferon beta-1a FDA Link 01/2022 - 01/2017
3	Cladribine FDA LinkGeneric 11/2022 - 11/2020
3	laquinimodIBA 04/2022 - 06/2016
3	Sphingosine-1-Phosphate ReceptorsIBA 01/2022 - 01/2018
3	Dimethyl FumarateIBA 01/2022 - 01/2020
3	Immunoglobulin G (IgG)IBA 01/2022 - 08/2007
3	Complement System Proteins (Complement)IBA 10/2021 - 01/2018
3	FumaratesIBA 01/2021 - 01/2020
3	diroximel fumarateIBA 01/2021 - 01/2020
3	siponimodIBA 07/2020 - 08/2013
3	AutoantibodiesIBA 01/2020 - 08/2007
3	Interferon-betaIBA 07/2019 - 09/2015
3	opicinumabIBA 12/2018 - 03/2017
3	Vasodilator Agents (Vasodilators)IBA 09/2015 - 02/2010
2	TabletsIBA 11/2022 - 01/2020
2	IntegrinsIBA 11/2021 - 01/2017
2	Phosphotransferases (Kinase)IBA 05/2021 - 01/2021
2	InterferonsIBA 01/2021 - 07/2019
2	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2021 - 07/2016
2	tau Proteins (tau Protein)IBA 01/2021 - 01/2021
2	AntigensIBA 01/2020 - 02/2007
2	Phosphates (Orthophosphate)IBA 01/2020 - 01/2018
2	CannabidiolIBA 01/2019 - 01/2019
2	Dronabinol (THC)FDA LinkGeneric 01/2019 - 01/2019
2	AntibodiesIBA 05/2015 - 08/2007
2	Methionine (L-Methionine)FDA Link 05/2015 - 05/2015
2	Bevacizumab (Avastin)FDA Link 05/2013 - 08/2009
2	oxidized low density lipoproteinIBA 11/2010 - 12/2009
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 06/2005 - 11/2002
1	NucleosidesIBA 11/2022
1	Phosphopyruvate Hydratase (Enolase)IBA 10/2022
1	N 30IBA 05/2022
1	teriflunomideIBA 01/2022
1	ofatumumab FDA Link 01/2022
1	ozanimodIBA 01/2022
1	2'-deoxyadenosineIBA 11/2021
1	ProdrugsIBA 11/2021
1	Interleukin-17 (Interleukin 17)IBA 07/2021
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021

Therapy/Procedure

53	Therapeutics 02/2022 - 11/2002
4	Blood Component Removal (Apheresis) 12/2019 - 12/2009
2	Injections 01/2022 - 12/2015
2	Drug Therapy (Chemotherapy) 01/2021 - 05/2013
2	Immunotherapy 01/2019 - 01/2017
2	Aftercare (After-Treatment) 01/2018 - 01/2015
2	Activities of Daily Living (ADL) 01/2017 - 12/2011
2	Immunomodulation 06/2014 - 02/2007
2	Magnetic Field Therapy 11/2011 - 05/2009
1	Deep Brain Stimulation 01/2022